TNF and ankylosing spondylitis: Indeed, data from the BSR Biologics Register for Ankylosing Spondylitis indicate that in a real-world patient population around half of patients respond to TNF inhibition [6], compared to > 60% in the clinical trials that led to the licensing of these agents.